Sionna Therapeutics, Inc. (SION) shareholders
Close on Nov 17, 2026Market cap $138.80MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (23.70%), Rajeev Shah (23.70%) and 2 more | 10,445,322 | 23.70% | 13D (active) | Feb 10, 2025 |
| James G. Coulter Joint filing with Tpg Gp A, LLC (15.20%), Jon Winkelried (15.20%) | 6,684,962 | 15.20% | 13D (active) | Feb 10, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (14.30%), Rajeev Shah (14.30%) and 1 more | 6,476,193 | 14.30% | 13D (active) amendment | Sep 17, 2026 |
| Orbimed Advisors LLC Joint filing with OrbiMed Capital GP VIII LLC (8.40%) | 3,704,959 | 8.40% | 13D (active) | Feb 10, 2025 |
| Shabet Rose Sharon Joint filing with Viking Global Investors LP (7.10%), Viking Global Opportunities Parent GP LLC (7.10%) and 1 more | 3,195,181 | 7.10% | 13G (passive) amendment | Mar 31, 2026 |
| OrbiMed Capital GP VIII LLC Joint filing with Orbimed Advisors LLC (6.60%) | 2,967,722 | 6.60% | 13D (active) amendment | Apr 15, 2026 |
| Atlas Venture Associates XI, L.P. Joint filing with Atlas Venture Fund XI, L.P. (6.50%), Atlas Venture Associates XI, LLC (6.50%) | 2,886,293 | 6.50% | 13D (active) | Feb 10, 2025 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (5.80%) | 2,639,418 | 5.80% | 13G (passive) | Sep 30, 2026 |
| Sionna Aggregator, LP Joint filing with Enavate Sciences GP, LLC (5.60%) | 2,478,030 | 5.60% | 13D (active) | Feb 10, 2025 |
| Atlas Venture Associates XI, LLC Joint filing with Atlas Venture Fund XI, L.P. (5.40%), Atlas Venture Associates XI, L.P. (5.40%) | 2,382,495 | 5.40% | 13D (active) amendment | Oct 16, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SION | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,905,045 | 21.91% | $435.72M | – | 3.79% |
| Tpg Gp A, LLC | 6,494,962 | 14.37% | $285.71M | – | 5.71% |
| Viking Global Investors LP | 3,195,181 | 7.07% | $140.56M | – | 0.40% |
| Atlas Venture Life Science Advisors, LLC | 2,995,602 | 6.63% | $131.78M | – | 14.95% |
| Orbimed Advisors LLC | 2,555,877 | 5.65% | $112.43M | −974,825 | 2.08% |
| Enavate Sciences Gp, LLC | 2,478,030 | 5.48% | $109.01M | – | 31.56% |
| Adage Capital Partners Gp, L.L.C. | 1,600,000 | 3.54% | $70.38M | +1,450,000 | 0.10% |
| JPMorgan Chase & Co | 1,490,508 | 3.30% | $64.09M | +25,494 | 0.00% |
| BlackRock, Inc. | 1,474,769 | 3.26% | $64.88M | +178,902 | 0.00% |
| Jennison Associates LLC | 1,172,133 | 2.59% | $51.56M | −279,087 | 0.03% |
| Citadel Advisors LLC | 1,147,636 | 2.54% | $50.48M | −19,295 | 0.01% |
| Vanguard Capital Management LLC | 1,132,001 | 2.50% | $49.80M | +102,504 | 0.00% |
| State Street Corp | 1,021,534 | 2.26% | $44.94M | +265,307 | 0.00% |
| Perceptive Advisors LLC | 905,000 | 2.00% | $39.81M | +246,561 | 0.60% |
| Deerfield Management Company, L.P. (Series C) | 680,916 | 1.51% | $29.95M | −289,674 | 0.31% |
| Siren, L.L.C. | 610,515 | 1.35% | $26.86M | +310,515 | 0.54% |
| Price T Rowe Associates Inc /Md/ | 478,016 | 1.06% | $21.03M | −278,360 | 0.00% |
| Eventide Asset Management, LLC | 474,981 | 1.05% | $20.89M | −170,549 | 0.28% |
| Geode Capital Management, LLC | 457,145 | 1.01% | $20.11M | +67,273 | 0.00% |
| Casdin Capital, LLC | 400,000 | 0.88% | $17.60M | New | 0.88% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 147 | 48M | 100.0% | 35 / 57 | 40 / 8 | 6M | 3M |
| Q1 2026 | 122 | 46M | 100.0% | 32 / 41 | 30 / 9 | 4M | 2M |
| Q4 2025 | 101 | 44M | 97.2% | 30 / 39 | 20 / 7 | 4M | 5M |
| Q3 2025 | 78 | 45M | 99.1% | 19 / 21 | 18 / 6 | 3M | 2M |
| Q2 2025 | 65 | 43M | 96.1% | 26 / 18 | 10 / 8 | 3M | 1M |
| Q1 2025 | 47 | 41M | 91.8% | 47 / 0 | 0 / 0 | 41M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
131 funds held SION in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SION | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 934,641 | 2.07% | $41.11M | 0.00% | Jun 30, 2026 |
| PGIM Jennison Health Sciences Fund | 651,048 | 1.44% | $27.88M | 2.01% | May 29, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 647,694 | 1.43% | $28.49M | 0.27% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 524,280 | 1.16% | $23.06M | 0.88% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 483,961 | 1.07% | $21.29M | 0.03% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 474,969 | 1.05% | $20.89M | 1.17% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 287,643 | 0.64% | $12.65M | 0.11% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 201,838 | 0.45% | $9.51M | 0.03% | Jul 31, 2026 |
| iShares Biotechnology ETF | 185,693 | 0.41% | $8.17M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 173,168 | 0.38% | $7.62M | 0.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 168,369 | 0.37% | $7.41M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 166,643 | 0.37% | $7.33M | 0.43% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 116,442 | 0.26% | $5.12M | 0.20% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 107,956 | 0.24% | $5.09M | 0.44% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 83,317 | 0.18% | $3.57M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Cloonan | President & CEO, Director | 765,393 | 1.69% | Sep 18, 2026 |
| Charlotte McKee | CMO and Head of R&D | 78,415 | 0.17% | Sep 18, 2026 |
| Elena Ridloff | CFO and CBO | 85,801 | 0.19% | Sep 18, 2026 |
| Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | 28,133 | 0.06% | Sep 18, 2026 |
| Caroline Stark Beer | Chief Business Officer | – | – | Jan 6, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 3,448,812 | 7.63% | Sep 21, 2026 |
| Capital Healthcare Fund LP RA | Director | – | – | Sep 21, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Sep 21, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 715,988 | 1.58% | Sep 21, 2026 |
| Peter Kolchinsky | Director, 10% owner | 2,198,082 | 4.86% | Sep 21, 2026 |
| RA Capital Nexus Fund, L.P. | Director | – | – | Sep 21, 2026 |
| Capital GP VIII LLC OrbiMed | Director | 2,469,959 | 5.46% | Jul 9, 2026 |
| Peter A. Thompson | Director | 2,469,959 | 5.46% | Jul 9, 2026 |
| Advisors Llc Orbimed | Director | 2,555,877 | 5.65% | Jul 9, 2026 |
| Harold Edward Fleming | Director | – | – | Jun 18, 2026 |
| Joanne L. Viney | Director | – | – | Jun 18, 2026 |
| Marcella K. Ruddy | Director | – | – | Jun 18, 2026 |
| Paul J. Clancy | Director | – | – | Jun 18, 2026 |
| Bruce Booth | Director | 3,057,453 | 6.76% | Jun 18, 2026 |
| Laurie Stelzer | Director | – | – | Jun 18, 2026 |
| Joshua Resnick | Director | – | – | Jun 18, 2026 |
| Lucian Iancovici | Director | – | – | Feb 6, 2025 |
| Jon Winkelried | 10% owner | 6,494,962 | 14.37% | Jan 26, 2026 |
| James G. Coulter | 10% owner | 6,744,962 | 14.92% | Jan 26, 2026 |
| Tpg Gp A, Llc | 10% owner | 6,684,962 | 14.79% | Jan 26, 2026 |
| Atlas Venture Fund XI, L.P. | 10% owner | 4,441,747 | 9.82% | Feb 10, 2025 |
| Atlas Venture Associates Opportunity II, LP | 10% owner | – | – | Feb 10, 2025 |
| Atlas Venture Opportunity Fund II, L.P. | 10% owner | – | – | Feb 10, 2025 |
| Atlas Venture Associates Opportunity II, LLC | 10% owner | – | – | Feb 10, 2025 |
| Atlas Venture Associates XI, LLC | 10% owner | – | – | Feb 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. Director, 10% owner | Sep 17, 2026 | Sale | −33,800 | $7.46 | $252.15K | 3,448,812 |
| Ra Capital Management, L.P. Director, 10% owner | Sep 17, 2026 | Sale | −3,415,011 | $6.32 | $21.58M | 3,482,612 |
| Charlotte McKee CMO and Head of R&D | Sep 17, 2026 | Award | +50,000 | – | – | 78,415 |
| Charlotte McKee CMO and Head of R&D | Sep 17, 2026 | Award | +50,000 | – | – | 128,415 |
| Jennifer Fitzpatrick CLO and Head of Program Mgmt. | Sep 17, 2026 | Award | +28,133 | – | – | 28,133 |
| Jennifer Fitzpatrick CLO and Head of Program Mgmt. | Sep 17, 2026 | Award | +28,132 | – | – | 56,265 |
| Elena Ridloff CFO and CBO | Sep 17, 2026 | Award | +47,269 | – | – | 85,801 |
| Elena Ridloff CFO and CBO | Sep 17, 2026 | Award | +47,268 | – | – | 133,069 |
| Michael Cloonan President & CEO, Director | Sep 17, 2026 | Award | +109,025 | – | – | 765,393 |
| Michael Cloonan President & CEO, Director | Sep 17, 2026 | Award | +109,025 | – | – | 656,368 |
| Peter A. Thompson Director | Jul 7, 2026 | Sale(10b5-1 plan) | −85,918 | $44.86 | $3.85M | 2,469,959 |
| Capital GP VIII LLC OrbiMed Director | Jul 7, 2026 | Sale(10b5-1 plan) | −85,918 | $44.86 | $3.85M | 2,469,959 |
| Jennifer Fitzpatrick Chief Legal Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −10,250 | $43.60 | $446.90K | 0 |
| Jennifer Fitzpatrick Chief Legal Officer | Jul 6, 2026 | Option exercise | +10,250 | $6.11 | $62.63K | 10,250 |
| Peter A. Thompson Director | Jun 30, 2026 | Sale(10b5-1 plan) | −115,844 | $45.50 | $5.27M | 2,555,877 |
| Advisors Llc Orbimed Director | Jun 30, 2026 | Sale(10b5-1 plan) | −115,844 | $45.50 | $5.27M | 2,555,877 |
| Advisors Llc Orbimed Director | May 27, 2026 | Sale(10b5-1 plan) | −101 | $44.49 | $4.49K | 2,671,721 |
| Peter A. Thompson Director | May 27, 2026 | Sale(10b5-1 plan) | −101 | $44.49 | $4.49K | 2,671,721 |
| Advisors Llc Orbimed Director | May 11, 2026 | Sale(10b5-1 plan) | −184,639 | $46.22 | $8.53M | 2,671,822 |
| Peter A. Thompson Director | May 11, 2026 | Sale(10b5-1 plan) | −184,639 | $46.22 | $8.53M | 2,671,822 |
| Advisors Llc Orbimed Director | May 8, 2026 | Sale(10b5-1 plan) | −59,767 | $44.58 | $2.66M | 2,856,461 |
| Peter A. Thompson Director | May 8, 2026 | Sale(10b5-1 plan) | −59,767 | $44.58 | $2.66M | 2,856,461 |
| Advisors Llc Orbimed Director | May 7, 2026 | Sale(10b5-1 plan) | −48,546 | $44.61 | $2.17M | 2,916,228 |
| Peter A. Thompson Director | May 7, 2026 | Sale(10b5-1 plan) | −48,546 | $44.61 | $2.17M | 2,916,228 |
| Peter A. Thompson Director | Apr 18, 2026 | Sale(10b5-1 plan) | −2,948 | $44.52 | $131.24K | 2,964,774 |
| Advisors Llc Orbimed Director | Apr 18, 2026 | Sale(10b5-1 plan) | −2,948 | $44.52 | $131.24K | 2,964,774 |
| Peter A. Thompson Director | Apr 17, 2026 | Sale(10b5-1 plan) | −52,397 | $44.68 | $2.34M | 2,967,722 |
| Advisors Llc Orbimed Director | Apr 17, 2026 | Sale(10b5-1 plan) | −52,397 | $44.68 | $2.34M | 2,967,722 |
| Peter A. Thompson Director | Apr 16, 2026 | Sale(10b5-1 plan) | −226,906 | $45.34 | $10.29M | 3,020,119 |
| Advisors Llc Orbimed Director | Apr 16, 2026 | Sale(10b5-1 plan) | −226,906 | $45.34 | $10.29M | 3,020,119 |
| Peter A. Thompson Director | Apr 15, 2026 | Sale(10b5-1 plan) | −235,863 | $44.64 | $10.53M | 3,247,025 |
| Advisors Llc Orbimed Director | Apr 15, 2026 | Sale(10b5-1 plan) | −235,863 | $44.64 | $10.53M | 3,247,025 |
| Peter A. Thompson Director | Apr 14, 2026 | Sale(10b5-1 plan) | −47,814 | $44.51 | $2.13M | 3,482,888 |
| Advisors Llc Orbimed Director | Apr 14, 2026 | Sale(10b5-1 plan) | −47,814 | $44.51 | $2.13M | 3,482,888 |
| Jennifer Fitzpatrick Chief Legal Officer | Mar 5, 2026 | Option exercise | +10,250 | $6.11 | $62.63K | 10,250 |
| Jennifer Fitzpatrick Chief Legal Officer | Mar 5, 2026 | Sale(10b5-1 plan) | −10,250 | $33.86 | $347.07K | 0 |
| Capital GP VIII LLC OrbiMed Director | Feb 3, 2026 | Sale(10b5-1 plan) | −29,063 | $44.58 | $1.30M | 3,530,702 |
| Peter A. Thompson Director | Feb 3, 2026 | Sale(10b5-1 plan) | −29,063 | $44.58 | $1.30M | 3,530,702 |
| Capital GP VIII LLC OrbiMed Director | Feb 2, 2026 | Sale(10b5-1 plan) | −1,890 | $44.57 | $84.24K | 3,559,765 |
| Peter A. Thompson Director | Feb 2, 2026 | Sale(10b5-1 plan) | −1,890 | $44.57 | $84.24K | 3,559,765 |
| Jon Winkelried 10% owner | Jan 22, 2026 | Sale | −250,000 | $40.00 | $10.00M | 6,494,962 |
| Capital GP VIII LLC OrbiMed Director | Dec 24, 2025 | Sale(10b5-1 plan) | −33,356 | $44.55 | $1.49M | 3,561,655 |
| Peter A. Thompson Director | Dec 24, 2025 | Sale(10b5-1 plan) | −33,356 | $44.55 | $1.49M | 3,561,655 |
| Capital GP VIII LLC OrbiMed Director | Dec 19, 2025 | Sale(10b5-1 plan) | −875 | $44.49 | $38.93K | 3,595,011 |
| Peter A. Thompson Director | Dec 19, 2025 | Sale(10b5-1 plan) | −875 | $44.49 | $38.93K | 3,595,011 |
| Capital GP VIII LLC OrbiMed Director | Dec 18, 2025 | Sale(10b5-1 plan) | −100 | $44.49 | $4.45K | 3,595,886 |
| Peter A. Thompson Director | Dec 18, 2025 | Sale(10b5-1 plan) | −100 | $44.49 | $4.45K | 3,595,886 |
| Capital GP VIII LLC OrbiMed Director | Dec 17, 2025 | Sale(10b5-1 plan) | −900 | $44.50 | $40.05K | 3,595,986 |
| Peter A. Thompson Director | Dec 17, 2025 | Sale(10b5-1 plan) | −900 | $44.50 | $40.05K | 3,595,986 |
| Jennifer Fitzpatrick Chief Legal Officer | Dec 5, 2025 | Option exercise | +10,250 | $6.11 | $62.63K | 10,250 |
| Jennifer Fitzpatrick Chief Legal Officer | Dec 5, 2025 | Sale(10b5-1 plan) | −10,250 | $40.52 | $415.33K | 0 |
| Peter A. Thompson Director | Nov 26, 2025 | Sale(10b5-1 plan) | −1,600 | $44.49 | $71.18K | 3,596,886 |
| Advisors Llc Orbimed Director | Nov 26, 2025 | Sale(10b5-1 plan) | −1,600 | $44.49 | $71.18K | 3,596,886 |
| Peter A. Thompson Director | Nov 25, 2025 | Sale(10b5-1 plan) | −11,890 | $44.60 | $530.29K | 3,598,486 |
| Advisors Llc Orbimed Director | Nov 25, 2025 | Sale(10b5-1 plan) | −11,890 | $44.60 | $530.29K | 3,598,486 |
| Peter A. Thompson Director | Nov 24, 2025 | Sale(10b5-1 plan) | −94,583 | $44.54 | $4.21M | 3,610,376 |
| Advisors Llc Orbimed Director | Nov 24, 2025 | Sale(10b5-1 plan) | −94,583 | $44.54 | $4.21M | 3,610,376 |
| Peter Kolchinsky Director, 10% owner | Nov 21, 2025 | Sale | −6,440 | $39.50 | $254.38K | 2,198,082 |
| Peter Kolchinsky Director, 10% owner | Nov 21, 2025 | Sale | −9,924 | $39.50 | $392.00K | 650,307 |
| Peter Kolchinsky Director, 10% owner | Nov 21, 2025 | Sale | −1,210 | $39.50 | $47.80K | 6,897,623 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sionna Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 99,175 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Sep 17, 2026 | 3,448,811 | $21.83M | Sep 17, 2026 | Private Transaction |
| Jennifer Fitzpatrick Officer | Jul 6, 2026 | 10,250 | $450.90K | Jul 6, 2026 | Exercise of Stock Options |
| OrbiMed Private Investments VIII, LP Shareholder | Jun 1, 2026 | 210,876 | $9.03M | May 29, 2026 | IPO |
| OrbiMed Private Investments VIII, LP Shareholder | May 29, 2026 | 1,082,480 | $46.33M | May 29, 2026 | IPO |
| Jennifer Fitzpatrick Officer | Mar 5, 2026 | 10,250 | $354.34K | Mar 5, 2026 | Exercise of Stock Options |
| Rise Fund Sling II, L.P. Stockholder | Jan 22, 2026 | 54,333 | $2.27M | Jan 22, 2026 | The shares of Common Stock reported herein were originally acquired by Seller upon the automatic conversion of shares of Preferred Stock of the Issuer into shares of Common Stock |
| Rise Fund Sling, L.P. Stockholder | Jan 22, 2026 | 195,667 | $8.17M | Jan 22, 2026 | The shares of Common Stock reported herein were originally acquired by Seller from Issuer and/or upon the automatic conversion of shares of Preferred Stock of the Issuer into shares of Common Stock. |
| Jennifer Fitzpatrick Officer | Dec 5, 2025 | 10,250 | $419.02K | Dec 5, 2025 | Exercise of Stock Options |
| OrbiMed Private Investments VIII, LP Shareholder | Nov 24, 2025 | 1,047,770 | $46.50M | Nov 24, 2025 | IPO |
| Blackwell Partners LLC - Series A Director, 10% Stockholder | Nov 21, 2025 | 7,609 | $332.21K | Nov 21, 2025 | Private Transaction |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Nov 21, 2025 | 9,924 | $433.28K | Nov 21, 2025 | Private Transaction |
| RA Capital Nexus Fund III, L.P. Director, 10% Stockholder | Nov 21, 2025 | 6,440 | $281.17K | Nov 21, 2025 | Private Funding |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Nov 21, 2025 | 1,210 | $52.83K | Nov 21, 2025 | Private Transaction |
| RA Capital Nexus Fund III, L.P. Director, 10% Stockholder | Nov 20, 2025 | 1,313 | $51.13K | Nov 20, 2025 | Private Funding |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Nov 20, 2025 | 2,023 | $78.78K | Nov 20, 2025 | Private Transaction |
See a number that looks wrong?